Skip to main content
. 2022 Jul 19;305(2):419–428. doi: 10.1148/radiol.220218

Figure 1:

(A) Standards for Reporting of Diagnostic Accuracy, or STARD, diagram of sample 1, men with newly diagnosed high-risk prostate cancer. (B) Standards for Reporting of Diagnostic Accuracy diagram of sample 2, men with biochemically recurrent prostate cancer. DCFPyL = 2-(3-{1-carboxy-5-[(6-[(18)F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid.

(A) Standards for Reporting of Diagnostic Accuracy, or STARD, diagram of sample 1, men with newly diagnosed high-risk prostate cancer. (B) Standards for Reporting of Diagnostic Accuracy diagram of sample 2, men with biochemically recurrent prostate cancer. DCFPyL = 2-(3-{1-carboxy-5-[(6-[(18)F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid.